Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Relapsed or Refractory Multiple Myeloma
Related studies linked through entity extraction aliases.
A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)
- Status
- COMPLETED
- Phase
- PHASE1
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3